Evidence & concentration worksheet · Bioregulators
Livagen 20 mg
Human efficacy and a validated dose have not been established for this compound. The former regimen has been withheld; only concentration arithmetic remains available.
Evidence review
No established human dosing protocol
Human efficacy and a validated dose have not been established for this compound. The former regimen has been withheld; only concentration arithmetic remains available.
How it works
Livagen is the tetrapeptide KEDA, marketed as a liver “bioregulator.” It has no FDA-approved product, liver indication, or dose.
Benefits & side effects
Studies exposed lymphocytes from older people to Livagen and measured chromatin changes.[1] Other work examined rat hepatocyte cultures and organotypic liver cultures.[2] These findings do not establish improved liver enzymes, fibrosis, fatty-liver disease, hepatitis outcomes, detoxification, or longevity in people.
Calculator
Concentration and measurement calculator
Use this only to check arithmetic from an authoritative product label, registered study protocol, or qualified clinician.
Arithmetic only — not a dose recommendation
Enter only a concentration and target supplied by an authoritative product label, a registered study protocol, or a qualified clinician. A correct conversion does not establish that a substance, vial, route, or dose is safe or effective.
Enter only a concentration and target supplied by an authoritative product label, a registered study protocol, or a qualified clinician. A correct conversion does not establish that a substance, vial, route, or dose is safe or effective.
Source concentration
Source-supplied target
References
References
- Bulletin of Experimental Biology and Medicine — Livagen and chromatin activation in lymphocytes from older people (2002)
- Bulletin of Experimental Biology and Medicine — Protein synthesis in rat hepatocyte cultures after Livagen exposure (2001)
- U.S. FDA — Understanding the risks of compounded drugs (2026)